SCHEMBL25968908

SCHEMBL25968908

CC(C)N1CCC(NC(=O)c2cc3nc(-c4ccccc4)cc(-c4ccccc4)n3n2)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.70
HTT P42858 4/20 0.70
ALDH1A1 P00352 9/20 0.56
HPGD P15428 8/20 0.56
LMNA P02545 5/20 0.56
NPSR1 Q6W5P4 4/20 0.56
TDP1 Q9NUW8 1/20 0.56
MAPK1 P28482 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 6/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
TP53 P04637 4/20 0.52
GAA P10253 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25968912 0.87 KDM4E (0.74) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25335602 0.87 KDM4E (0.74) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25338396 0.87 KDM4E (0.74) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25968910 0.86 KDM4E (0.71) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25969033 0.85 KDM4E (0.80) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25969141 0.83 KDM4E (0.77) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25430390 0.83 KDM4E (0.96) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL1718809 0.83 KDM4E (1.00) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL25969031 0.82 KDM4E (0.69) KDM4EHTTALDH1A1HPGDLMNA
SCHEMBL4201226 0.82 KDM4E (0.98) KDM4EHTTALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2025-05-22 US disclosed
EP-4469454-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE Janssen Pharmaceutica NV (BE) 2024-12-04 EP disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE SMOX, SRM, SMS KDM4E 1480/4885HTT 3140/4885ALDH1A1 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.